

LIST OF FIGURES

Figure I.1.	Structure of Merrifield Resin	2
Figure I.2.	A schematic diagram of the apoferritin	6
Figure I.3.	A schematic presentation for the synthesis of metal–organic framework (MOF)	8
Figure I.4.	Structures of poly(<i>N</i> -vinyl-2-pyrrolidone) (PVP) and poly(2,5-dimethylphenylene oxide) (PPO)	8
Figure I.5.	Structure of Chitin and Chitosane	10
Figure I.6.	Structures of various ion–exchange resins	12
Figure II.1.	Schematic preparative steps of Pd/Fe–ARF–110 nanocomposites	22
Figure II.2.	Photographic images of six nanocomposites	22
Figure II.3.	FT–IR spectra of ARF, Fe–ARF and Pd/Fe–ARF bimetallic nanocomposites	23
Figure II.4.	The powder XRD patterns of six nanocomposites prepared under different conditions	25
Figure II.5.	The SEM images of (a) ARF; (b) Fe–ARF–110; (c) Pd/Fe–ARF–80; (d) Pd/Fe–ARF–110; (e) Pd/Fe–ARF–140; (f) Pd/Fe–ARF–110–OA and (g) Pd/Fe–ARF–110–NaOA nanocomposites, respectively	27
Figure II.6.	TEM images: (a) of Fe–ARF–110 and (b) its average particle size distribution histogram from (a); (c) of Pd/Fe–ARF–110 and (d) its average particle size distribution histogram from (c); (e) of Pd/Fe–ARF–110–OA and (f) its average particle size distribution histogram from (e); (g) of Pd/Fe–ARF–110–NaOA and (h) its average particle size distribution histogram from (g)	28
Figure II.7.	(a) TEM–EDX spectrum of Pd/Fe–ARF–110 nanocomposites; (b) EDX elemental mapping image of Pd/Fe ₂ O ₃ bimetallic nanocomposites, green dots, Pd; red dots, Fe	29
Figure II.8.	Recycling experiments using Pd/Fe–ARF–110 catalyst in hydrodebromination of 9, 10–dibromoanthracene	33
Figure III.A.1.	(a) Hydrated small hydrophobic aggregates, (b) hydrated large hydrophobic aggregates	42
Figure III.B.1.	The chemical structure of trityl losertan	48
Figure III.B.2.	Structures of some drugs and pharmaceuticals containing biphenyl moiety	49
Figure III.B.3.	Structures of some analgesic drugs synthesized by SM coupling reaction	49

Figure III.B.4.	Biphenyls used in materials science	50
Figure III.C.1.	Vinyl sulfides used as synthetic intermediates.	71
Figure III.C.2.	Vinyl sulfides used as biologically active molecules	71
Figure III.C.3.	Structures of Ni–NHC complex and some NHCs	76
Figure IV.1	Structures of carbamic acid, thiocarbamic acid and dithiocarbamic acid and their esters	92
Figure IV.2.	Examples of compounds of potential therapeutic value bearing <i>S</i> -alkyl carbodithioate esters function	93
Figure IV.3.	HRMS of compound 4b	102
Figure V.1.	¹ H–NMR spectra of L1 [1,3-bis(4-fluorophenylthio)–propane] in d ₆ –DMSO	123
Figure V.2.	¹ H–NMR spectra of complex 1 in d ₆ –DMSO	124
Figure V.3.	UV–Visible spectra of CuI, L1 and complex 1 were taken in MeCN	125
Figure V.4.	Fluorescence spectrum of complex 1 (5 μM solution) in MeCN solvent	125
Figure V.5.	View of (a) the monomeric unit of the coordination polymer, (b) ORTEP picture of the complex 1 and (c) infinite 1–D chain of complex 1 incorporating dinuclear Cu(μ ₂ -I) ₂ Cu motifs along ‘ <i>b</i> ’ axis	127